Logo image of TGAN

TRANSPHORM INC (TGAN) Stock Fundamental Analysis

NASDAQ:TGAN - Nasdaq - US89386L1008 - Common Stock - Currency: USD

5.1  +0.34 (+7.14%)

After market: 5.0998 0 (0%)

Fundamental Rating

2

Overall TGAN gets a fundamental rating of 2 out of 10. We evaluated TGAN against 108 industry peers in the Semiconductors & Semiconductor Equipment industry. The financial health of TGAN is average, but there are quite some concerns on its profitability. TGAN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TGAN had negative earnings in the past year.
In the past year TGAN has reported a negative cash flow from operations.
TGAN had negative earnings in each of the past 5 years.
In the past 5 years TGAN always reported negative operating cash flow.
TGAN Yearly Net Income VS EBIT VS OCF VS FCFTGAN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

TGAN has a worse Return On Assets (-127.67%) than 94.44% of its industry peers.
The Return On Equity of TGAN (-228.50%) is worse than 86.11% of its industry peers.
Industry RankSector Rank
ROA -127.67%
ROE -228.5%
ROIC N/A
ROA(3y)-56.82%
ROA(5y)-113.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TGAN Yearly ROA, ROE, ROICTGAN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -10K -20K -30K

1.3 Margins

TGAN has a worse Gross Margin (18.77%) than 78.70% of its industry peers.
TGAN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 18.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TGAN Yearly Profit, Operating, Gross MarginsTGAN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

4

2. Health

2.1 Basic Checks

TGAN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TGAN has been increased compared to 1 year ago.
Compared to 1 year ago, TGAN has a worse debt to assets ratio.
TGAN Yearly Shares OutstandingTGAN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
TGAN Yearly Total Debt VS Total AssetsTGAN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of 0.88, we must say that TGAN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.88, TGAN is doing worse than 72.22% of the companies in the same industry.
TGAN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.88
ROIC/WACCN/A
WACC12.3%
TGAN Yearly LT Debt VS Equity VS FCFTGAN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M -20M

2.3 Liquidity

A Current Ratio of 1.69 indicates that TGAN should not have too much problems paying its short term obligations.
TGAN's Current ratio of 1.69 is on the low side compared to the rest of the industry. TGAN is outperformed by 77.78% of its industry peers.
TGAN has a Quick Ratio of 1.69. This is a bad value and indicates that TGAN is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.88, TGAN is doing worse than 86.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.69
Quick Ratio 0.88
TGAN Yearly Current Assets VS Current LiabilitesTGAN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for TGAN have decreased by -7.32% in the last year.
Looking at the last year, TGAN shows a small growth in Revenue. The Revenue has grown by 2.74% in the last year.
Measured over the past years, TGAN shows a quite strong growth in Revenue. The Revenue has been growing by 11.44% on average per year.
EPS 1Y (TTM)-7.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.25%
Revenue 1Y (TTM)2.74%
Revenue growth 3Y11.44%
Revenue growth 5YN/A
Sales Q2Q%4.01%

3.2 Future

TGAN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.24% yearly.
Based on estimates for the next years, TGAN will show a very strong growth in Revenue. The Revenue will grow by 45.75% on average per year.
EPS Next Y24.61%
EPS Next 2Y18.84%
EPS Next 3Y8.24%
EPS Next 5YN/A
Revenue Next Year37.91%
Revenue Next 2Y49.23%
Revenue Next 3Y45.75%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TGAN Yearly Revenue VS EstimatesTGAN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M 50M
TGAN Yearly EPS VS EstimatesTGAN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -0.1 -0.2 -0.3 -0.4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TGAN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TGAN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TGAN Price Earnings VS Forward Price EarningsTGAN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TGAN Per share dataTGAN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.84%
EPS Next 3Y8.24%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TGAN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRANSPHORM INC

NASDAQ:TGAN (6/20/2024, 8:00:00 PM)

After market: 5.0998 0 (0%)

5.1

+0.34 (+7.14%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)06-25 2024-06-25/amc
Earnings (Next)08-12 2024-08-12/amc
Inst Owners2.78%
Inst Owner Change0%
Ins Owners0.19%
Ins Owner Change0%
Market Cap323.14M
Analysts77.78
Price Target5.66 (10.98%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-18.74%
Min EPS beat(2)-19.83%
Max EPS beat(2)-17.65%
EPS beat(4)1
Avg EPS beat(4)-6.44%
Min EPS beat(4)-19.83%
Max EPS beat(4)30.28%
EPS beat(8)2
Avg EPS beat(8)-9.45%
EPS beat(12)5
Avg EPS beat(12)17.27%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-16.54%
Min Revenue beat(2)-25.76%
Max Revenue beat(2)-7.33%
Revenue beat(4)0
Avg Revenue beat(4)-17.17%
Min Revenue beat(4)-32.96%
Max Revenue beat(4)-2.66%
Revenue beat(8)2
Avg Revenue beat(8)-9.25%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)6.25%
EPS NQ rev (3m)6.25%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)8.08%
Revenue NQ rev (3m)8.08%
Revenue NY rev (1m)2.63%
Revenue NY rev (3m)2.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.23
P/FCF N/A
P/OCF N/A
P/B 17.71
P/tB 18.86
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)-0.27
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0.3
BVpS0.29
TBVpS0.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -127.67%
ROE -228.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 18.77%
FCFM N/A
ROA(3y)-56.82%
ROA(5y)-113.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 166.21%
Cap/Sales 10.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.69
Quick Ratio 0.88
Altman-Z 0.88
F-Score4
WACC12.3%
ROIC/WACCN/A
Cap/Depr(3y)264.68%
Cap/Depr(5y)166.9%
Cap/Sales(3y)15.02%
Cap/Sales(5y)14.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.25%
EPS Next Y24.61%
EPS Next 2Y18.84%
EPS Next 3Y8.24%
EPS Next 5YN/A
Revenue 1Y (TTM)2.74%
Revenue growth 3Y11.44%
Revenue growth 5YN/A
Sales Q2Q%4.01%
Revenue Next Year37.91%
Revenue Next 2Y49.23%
Revenue Next 3Y45.75%
Revenue Next 5YN/A
EBIT growth 1Y-22.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-64.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.3%
OCF growth 3YN/A
OCF growth 5YN/A